Acta Scientific Paediatrics (ISSN: 2581-883X)

Research Article Volume 5 Issue 3

Chemotherapy Induced Sinusoidal Obstruction Syndrome in Children

Begümhan Demir Gündoğan*

Professor, Department of Pediatric Oncology, Mersin University, Los Angeles, USA

*Corresponding Author: Begümhan Demir Gündoğan, Professor, Department of Pediatric Oncology, Mersin University, Los Angeles, USA.

Received: December 24, 2021; Published: February 04, 2022


Sinusoidal obstruction syndrome (SOS) is a life-threatening complication that usually develops as a result of conditioning regimens for hematopoietic stem cell transplantation (HSCT). It is also less diagnosed after the use of chemotherapeutic agents, removal of alkaloid toxins, high-dose radiation therapy, or liver transplantation. It presents with hepatomegaly, right upper quadrant pain, jaundice and ascites [1-3]. Outside of the HSCT setting, only a few cases of SOS with Wilms tumor, rhabdomyosarcoma, acute lymphoblastic leukemia, and medulloblastoma have been reported. Here, we wanted to present our experience in 5 pediatric cases with SOS due to conventional treatment.

Keywords: Veno-Occlusive Disease; Hematopoetic Stem Cell Transplantation; Child


  1. Mohty M., et al. “Sinusoidal obstruction syndrome/Venoocclusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)”. Bone Marrow Transplant 50 (2015): 781-789.
  2. Chao N. “How I treat sinusoidal obstruction syndrome”. Blood 123 (2014): 4023-4026.
  3. Richardson PG., et al. “Defibrotide sodium for the treatment of hepatic Venoocclusive disease/sinusoidal obstruction syndrome”. Expert Review of Clinical Pharmacology 11 (2018): 113-124.
  4. Cefalo MG., et al. “Hepatic Venoocclusive disease: a chemotherapy-related toxicity in children with malignancies”. Paediatric Drugs 12 (2010): 277-284.
  5. Richardson PG., et al. “Defibrotide sodium for the treatment of hepatic Venoocclusive disease/sinusoidal obstruction syndrome”. Expert Review of Clinical Pharmacology 11 (2018): 113-124.
  6. Richardson PG., et al. “Phase 3 trial of defibrotide for the treatment of severe Venoocclusive disease and multi-organ failure”. Blood 127 (2016): 1656-1664.
  7. Carreras E., et al. “The incidence of Venoocclusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade”. Blood Marrow Transplant11 (2011): 1713-1720.
  8. Bearman SI. “The syndrome of hepatic Venoocclusive disease after marrow transplantation”. Blood 11 (1995): 3005-3020.
  9. Corbacioglu S., et al. “Diagnosis and severity criteria for sinusoidal obstruction syndrome/venoocclusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation”. Bone Marrow Transplant 53 (2018): 138-145.
  10. Faraci M., et al. “Sinusoidal Obstruction Syndrome/Venoocclusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association Hematopoietic Stem Cell Transplantation Group”. Biology of Blood Marrow Transplant 25 (2019): 313-320.
  11. Kallianpur AR., et al. “The hemochromatosis C282Y allele: a risk factor for hepatic Venoocclusive disease after hematopoietic stem cell transplantation”. Bone Marrow Transplant 35 (2005): 1155-1164.
  12. Efrati E., et al. “MTHFR C677T/A1298C genotype: a possible risk factor for liver sinusoidal obstruction syndrome”. Bone Marrow Transplant 49 (2014): 726-727.
  13. Srivastava A., et al. “Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation”. Blood 104 (2004): 1574-1577.
  14. Jones RJ., et al. “Venoocclusive disease of the liver following bone marrow transplantation”. Transplantation 44 (1987): 778-783.
  15. McDonald GB., et al. “Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors”. Hepatology 4 (1984): 116-122.
  16. Dignan FL., et al. “BCSH/BSBMT guideline: diagnosis and management of Venoocclusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation”. British Journal of Haematology 163 (2013): 444-457.
  17. Helmy A. “Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome”. Alimentary Pharmacology and Therapeutics 23 (2006): 11-25.
  18. DeLeve LD and Wang X. “Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes”. Pharmacology 60 (2000): 143-154.
  19. Richardson P and Guinan E. “Hepatic Venoocclusive disease following hematopoietic stem cell transplantation”. Acta Haematology 106 (2001): 57-68.


Citation: Begümhan Demir Gündoğan. “Chemotherapy Induced Sinusoidal Obstruction Syndrome in Children”. Acta Scientific Paediatrics 5.3 (2022): 34-38.


Copyright: © 2022 Begümhan Demir Gündoğan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor1.197

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US